ZZZhao-Chong Zeng

Zhao-Chong Zeng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhao-Chong Zeng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 25 April 2006
      • Vol. 12  (2) , 113-22

    Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients.

    by Zhao-Chong Zeng, Zhao-You Tang, Jia Fan, Jian Zhou, Lun-Xiu Qin, Shen-Long Ye, Hui-Chuan Sun, Bin-Liang Wang, Duo Li, Jian-Hua Wang, et al.

    The role of radiotherapy in the treatment of intrahepatic cholangiocarcinoma is controversial. We undertook this study to determine if radiotherapy is appropriate for patients with unresectable or lymph node metastatic intrahepatic cholangiocarcinoma. The records of 75 patients with intrahepatic cholangiocarcinoma were reviewed and analyzed by Kaplan-Meier method and Cox proportional hazards analysis. Thirty-eight patients who received limited local external-beam radiotherapy were classified as the radiotherapy group. This group included nine patients with resected intrahepatic cholangiocarcinoma with macroscopic residual lymph nodes receiving postoperative external-beam radiotherapy, seven patients with postoperative recurrences in lymph nodes receiving external-beam radiotherapy for salvage failure after treatment with surgery alone, and 22 patients with unresectable intrahepatic cholangiocarcinoma. The median total dose was 50 Gy (range, 30-60 Gy) in daily doses of 2 Gy/fraction, five times a week. Thirty-seven patients with intrahepatic cholangiocarcinoma (including 14 with resectable disease and synchronous or asynchronous lymph node metastases, and 23 with unresectable disease) who did not receive external-beam radiotherapy were selected from hospitalized patients in the same period and were classified as the nonexternal-beam radiotherapy group. Parameters observed included survival rates and tumor response to external-beam radiotherapy demonstrated both by clinical symptoms and by computed tomography scan/magnetic resonance image. Objective responses to external-beam radiotherapy were 36.4% for intrahepatic tumors in 22 patients with unresectable intrahepatic cholangiocarcinoma, and 52% for lymph node metastases in 25 patients with resectable or unresectable intrahepatic cholangiocarcinoma. Pain was relieved in 90% of the patients who received external-beam radiotherapy. The survival rates at 1 and 2 years for patients with unresectable intrahepatic cholangiocarcinoma treated with external-beam radiotherapy (n = 22) compared with those who did not receive external-beam radiotherapy (n = 23) were 36.1% versus 19.0% and 5.2% versus 4.7%, respectively (log-rank P = 0.021). The survival experience of the 16 patients with lymph node metastases (synchronous or asynchronous) who underwent hepatectomy combined with external-beam radiotherapy was superior to that of the group (n = 14) who did not receive external-beam radiotherapy (median survival, 468 and 211 days, respectively; log-rank P = 0.075). These results show that external-beam radiotherapy influenced the survival in the patients with unresectable intrahepatic cholangiocarcinoma or lymph node metastases. The most common reason for death was liver failure caused by uncontrolled intrahepatic disease. Grade 3 toxicity in the external-beam radiotherapy group was infrequent. External-beam radiotherapy seems to improve the prognosis of patients with unresectable intrahepatic cholangiocarcinoma and deserves further study.


  • A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus

    by Zhao-Chong Zeng, Jia Fan, Zhao-You Tang, Jian Zhou, Lun-Xiu Qin, Jian-Hua Wang, Hui-Chuan Sun, Bin-Liang Wang, Jian-Ying Zhang, Guo-Liang Jiang, et al.


  • Open Access

    Radiation Therapy for Adrenal Gland Metastases from Hepatocellular Carcinoma

    by Zhao-Chong Zeng, Zhao-You Tang, Jia Fan, Jian Zhou, Lun-Xiu Qin, Shen-Long Ye, Hui-Chuan Sun, Bin-Liang Wang, Jian-Ying Zhang, Yao Yu, et al.

    Background: The adrenal gland is a common site of extrahepatic metastases from hepatocellular carcinoma. However, it has been the subject of few studies, and the optimal treatment remains unclear. Methods previously tried for the management of adrenal gland metastasis of hepatocellular carcinoma included surgical resection, transarterial chemoembolization or percutaneous ethanol injection, on the basis of case reports. External beam radiation therapy has seldom been applied for patients with adrenal gland metastases. Methods: We retrospectively studied 22 patients with adrenal metastases from hepatocellular carcinoma who were treated with limited-field external beam radiation therapy. The radiation dose to the adrenal lesion ranged from 36 to 54 (median 50) Gy, while the intrahepatic lesions were treated with either surgical resection or transarterial chemoembolization. Results: Among the 14 patients who had pain related to adrenal metastases, 11 (78.6%) had complete pain relief without medication that lasted until death. Two (14.3%) patients had marked pain relief, but still required analgesics. Partial responses were observed in 73% of the patients. The median survival period for all patients was 10 months. No patient died from complications related to adrenal metastasis. Adverse effects were mild. Conclusion: Adrenal metastases from hepatocellular carcinoma are sensitive to radiation treatment. Radiation therapy with 50 Gy for adrenal gland metastases is a good palliative therapy with reasonable safety.